Peripheral neutrophil inclusions in amiodarone treated patients.
Open Access
- 1 December 1986
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 22 (6) , 736-738
- https://doi.org/10.1111/j.1365-2125.1986.tb02968.x
Abstract
In 14 patients receiving chronic amiodarone therapy the appearance of multilamellar inclusion bodies in peripheral blood neutrophils was related to both plasma concentrations of amiodarone and its desethyl metabolite and unwanted effects of the drug. Seven of the patients had well defined inclusion bodies. In this group mean amiodarone and desethylamiodarone concentrations were significantly higher than in the remaining seven patients and all but one had unwanted effects of the drug. Of the seven patients without inclusion bodies only one, with high plasma amiodarone and desethylamiodarone concentrations, had unwanted effects of the drug. It is concluded that the appearance of multilamellar bodies in the blood neutrophils of amiodarone-treated patients may help to distinguish those patients at risk of long-term amiodarone toxicity.This publication has 5 references indexed in Scilit:
- Amiodarone pharmacokinetics.1986
- Amiodarone and its desethyl metabolite: tissue distribution and morphologic changes during long-term therapy.Circulation, 1985
- Electron microscopic demonstration of lysosomal inclusion bodies in lung, liver, lymph nodes, and blood leukocytes of patients with amiodarone pulmonary toxicityThe American Journal of Medicine, 1985
- Amiodarone pharmacokineticsAmerican Heart Journal, 1983
- High-Performance Liquid Chromatographic Measurement of Amiodarone and Its Desethyl MetaboliteTherapeutic Drug Monitoring, 1982